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Abstract
Objective:  To  identify  chromosomal  imbalances  by  whole-genome  microarray-based  compara-
tive genomic  hybridization  (array-CGH)  in  DNA  samples  of  neonates  with  congenital  anomalies
of  unknown  cause  from  a  birth  defects  monitoring  program  at  a  public  maternity  hospital.
Methods:  A  blind  genomic  analysis  was  performed  retrospectively  in  35  stored  DNA  samples  of
neonates  born  between  July  of  2011  and  December  of  2012.  All  potential  DNA  copy  number
variations  detected  (CNVs)  were  matched  with  those  reported  in  public  genomic  databases,
and  their  clinical  signiﬁcance  was  evaluated.
Results:  Out  of  a  total  of  35  samples  tested,  13  genomic  imbalances  were  detected  in  12/35
cases (34.3%).  In  4/35  cases  (11.4%),  chromosomal  imbalances  could  be  deﬁned  as  pathogenic;
in  5/35  (14.3%)  cases,  DNA  CNVs  of  uncertain  clinical  signiﬁcance  were  identiﬁed;  and  in  4/35
cases  (11.4%),  normal  variants  were  detected.  Among  the  four  cases  with  results  considered
causally related  to  the  clinical  ﬁndings,  two  of  the  four  (50%)  showed  causative  alterations
already  associated  with  well-deﬁned  microdeletion  syndromes.  In  two  of  the  four  samples  (50%),
the  chromosomal  imbalances  found,  although  predicted  as  pathogenic,  had  not  been  previously
associated  with  recognized  clinical  entities.
Conclusions:  Array-CGH  analysis  allowed  for  a  higher  rate  of  detection  of  chromosomal  anoma-
lies, and  this  determination  is  especially  valuable  in  neonates  with  congenital  anomalies  of
unknown  etiology,  or  in  cases  in  which  karyotype  results  cannot  be  obtained.  Moreover,  although
the  interpretation  of  the  results  must  be  reﬁned,  this  method  is  a  robust  and  precise  tool  that
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can  be  used  in  the  ﬁrst-line  investigation  of  congenital  anomalies,  and  should  be  considered  for
prospective/retrospective  analyses  of  DNA  samples  by  birth  defect  monitoring  programs.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Hibridizac¸ão  genômica  comparativa  baseada  em  microarranjos  em  neonatos  com
anomalias  congênitas:  detecc¸ão  de  desequilíbrios  cromossômicos
Resumo
Objetivo:  Identiﬁcar  desequilíbrios  cromossômicos  por  meio  da  hibridizac¸ão  genômica  compa-
rativa baseada  em  microarranjos  (CGH-array)  em  amostras  de  DNA  de  neonatos  com  anomalias
congênitas  de  causa  desconhecida  de  um  programa  de  monitoramento  de  defeitos  congênitos
em  uma  maternidade  pública.
Métodos: Uma  análise  genômica  cega  foi  realizada  retrospectivamente  em  35  amostras
armazenadas de  DNA  de  neonatos  nascidos  entre  julho  de  2011  e  dezembro  de  2012.  Todas
as  possíveis  variac¸ões  no  número  de  cópias  (CNVs)  de  DNA  foram  comparadas  com  as  relatadas
em  bases  de  dados  genômicos  públicas,  e  sua  relevância  clínica  foi  avaliada.
Resultados: De  um  total  de  35  amostras  testadas,  foram  detectados  13  desequilíbrios  genômicos
em 12/35  casos  (34,3%).  Em  4/35  casos  (11,4%),  os  desequilíbrios  cromossômicos  poderiam  ser
deﬁnidos  como  patogênicos;  em  5/35  (14,3%)  deles  foram  identiﬁcadas  CNVs  de  DNA  de  relevân-
cia  clínica  incerta;  e,  em  4/35  (11,4%),  foram  detectadas  variac¸ões  normais.  Dentre  os  quatro
casos  com  resultados  considerados  relacionados  causalmente  aos  achados  clínicos,  2/4  (50%)
apresentaram  alterac¸ões  causais  já  relacionadas  a  síndromes  de  microdelec¸ão  bem  deﬁnidas.
Em 2/4  amostras  (50%),  os  desequilíbrios  cromossômicos  encontrados,  embora  preditivos  como
patogênicos,  não  estavam  relacionados  anteriormente  a  entidades  clínicas  reconhecidas.
Conclusões: A  análise  de  CGH-array  permitiu  maior  taxa  de  detecc¸ão  de  anomalias  cromossômi-
cas, e  essa  determinac¸ão  é  valiosa  principalmente  em  neonatos  com  anomalias  congênitas  de
etiologia  desconhecida  ou  em  casos  em  que  os  resultados  do  cariótipo  não  podem  ser  obtidos.
Além  disso,  embora  a  interpretac¸ão  dos  resultados  deva  ser  reﬁnada,  esse  método  é  uma  fer-
ramenta  robusta  e  precisa  que  pode  ser  usada  na  investigac¸ão  de  primeira  linha  de  anomalias
congênitas  e  deve  ser  considerada  em  análises  futuras/retrospectivas  de  amostras  de  DNA  por
programas  de  monitoramento  de  defeitos  congênitos.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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lthough  Mendelian,  chromosomal,  and  environmental
auses have  been  established  for  many  congenital  anoma-
ies and  dysmorphic  syndromes,  the  precise  etiology  of
everal such  conditions  has  not  yet  been  identiﬁed.  Etiologic
nvestigations of  congenital  anomalies  suggest  that  6%  of
irth defects  are  related  to  chromosomal  abnormalities.1
owever,  the  proportion  of  chromosomal  anomalies  in  birth
efects may  be  higher.  Some  individuals  with  congenital
nomalies may  have  genomic  imbalances  below  the  resolu-
ion (>  5  Mb)  of  standard  chromosome  analysis.  In  the  last
ecade, signiﬁcant  developments  in  the  molecular  detec-
ion of  chromosomal  imbalances  have  occurred,  and  their
ausal relationship  to  congenital  anomalies  and  mental
isabilities has  increased.  The  considerable  gap  between
he resolution  for  detection  of  chromosome  abnormalities
ith light  microscopy  and  molecular  gene  analysis  was
ridged with  the  introduction  of  molecular  approaches,
uch as  microarray-based  comparative  genomic  hybridiza-
ion (array-CGH).  Array-CGH  is  currently  a  powerful  method
or the  simultaneous  detection  of  chromosomal  imbalances
r
a
i
pnd  the  most  prevalent  chromosome  abnormalities.  It
llows for  the  detection  of  trisomies  and  large  chromosomal
nomalies (already  recognized  by  standard  karyotype
nalysis) as  well  as  smaller  submicroscopic  chromosomal
mbalances (deletions,  duplications,  or  triplications  of
ny chromosomal  region,  few  of  which  are  recognized  by
uorescence in  situ  hybridization  [FISH])  that  result  in
opy-number variations  (CNVs).  Several  studies  have  shown
hat the  use  of  array-based  technologies  increases  the
etection rate  of  chromosomal  abnormalities  to  approxi-
ately 14%  to  18%,  compared  with  a  rate  of  approximately
% (excluding  trisomy  21)  using  standard  cytogenetic
pproaches in  individuals  with  developmental  delays,
ntellectual disabilities,  learning  difﬁculties,  multiple  con-
enital abnormalities  (MCAs),  autistic  spectrum  disorders,
chizophrenia, and  other  neuropsychiatric  disorders.2 The
verall frequency  of  unbalanced  chromosome  abnormalities
as reported  in  neonates  as  0.43%,  according  to  recent
3,4eports. Therefore,  the  introduction  of  genome-wide
rray-CGH analysis  at  the  neonatal  period,  when  few  clin-
cal ﬁndings  related  to  recognized  causes  may  be  present,
otentially increases  the  possibility  of  early  detection  of
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chromosomal  abnormalities  consistent  with  a  genetic/
genomic disorder.
Therefore,  the  aim  of  this  study  was  to  identify  chro-
mosomal imbalances  using  a  retrospective  whole-genome
array-CGH analysis  in  stored  DNA  samples  of  neonates  with
congenital anomalies  of  unknown  cause.  In  addition,  this
study evaluated  the  contribution  of  array-CGH  as  a ﬁrst-
line diagnostic  tool  in  neonates  with  congenital  anomalies
evaluated by  a  birth  defects  monitoring  program  at  a public
maternity hospital  in  Southern  Brazil.
Methods
Sample  selection
This  retrospective  study  was  performed  using  de-identiﬁed
DNA samples  extracted  from  the  blood  of  neonates,  which
were obtained  from  the  biorepository  of  the  Programa  de
Monitoramento de  Defeitos  Congênitos  (PMDC)  of  Hospi-
tal de  Clínicas  de  Porto  Alegre  (HCPA),  Brazil.  Subjects
were less  than  30  days  of  age,  presenting  a  wide  range
of congenital  anomalies  of  unknown  cause  and  in  whom  a
chromosomal abnormality  was  suspected.  The  clinical  indi-
cations  for  cytogenetic  analysis  at  the  time  of  referral  were
taken from  the  clinical  and  laboratory  data  collected  at
birth and  available  in  hospital  records,  and  did  not  include
follow-up investigations  and  information  about  disease  out-
comes. Cases  without  enough  clinical  data  were  excluded,
as were  cases  where  mothers  had  clinical  or  laboratory
suspicion of  infectious/parasitic  diseases  or  a  history  of
use/abuse of  illicit  drugs/alcohol  during  pregnancy.  Accord-
ing to  these  criteria,  a  total  of  45  samples  were  selected,
but ten  were  excluded  because  they  did  not  achieve  the
optimal DNA  quality  needed  for  the  array-CGH  analysis,  and
thus, the  study  was  conducted  with  35  samples.  The  results
of previous  chromosome  analyses  were  obtained  in  32  cases.
Conventional cytogenetic  testing  at  the  500-550  band  level
resolution was  initially  normal  for  all  cases,  but  in  one  case
a report  of  an  abnormal  karyotype  was  provided  later.  This
study was  approved  by  the  Institutional  Review  Board  of  the
HCPA and  was  conducted  in  accordance  with  current  institu-
tional ethics  rules  regarding  the  use  of  biological  materials
from biorepositories.5
Whole-genome  Array-CGH
Oligonucleotide  array-based  CGH  was  performed  using  an
8 ×  60  k  whole-genome  platform  (design  021924,  Agilent
Technologies, Santa  Clara,  USA),  which  has  an  average  spac-
ing of  40  kb  between  probes.  Genomic  DNA  was  isolated
from the  peripheral  blood  (provided  by  the  PMDC-HCPA)
of 35  neonatal  individuals  and  subsequently  analyzed.  For
each experiment,  a  gender-mismatched  normal  reference
(Promega Corp.  Madison,  WI,  USA)  was  used.  The  exper-
iments were  performed  according  to  the  manufacturer’s
protocol. Images  of  the  arrays  were  taken  using  a  microar-
ray scanner  (design  G2600D,  Agilent,  California,  USA)  and
processed using  Feature  Extraction  software  (design  v9.5.1,
Agilent, California,  USA),  both  from  Agilent.  The  raw  data
were analyzed  by  Agilent  Cytogenomics  (design  v2.7.8.0,
Agilent, California,  USA)  software  with  the  statistical
s
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lgorithm  ADM-2,  using  a  threshold  of  6.0  and  a  four-probe
inimum aberration  call.  Subsequent  software  normaliza-
ion of  the  data  was  performed  for  the  veriﬁcation  of  DNA
opy number  changes.  The  p-values  for  each  probe  were
alculated, providing  additional  objective  statistical  crite-
ia to  determine  whether  the  deviation  of  each  probe  from
ero was  statistically  signiﬁcant.6 All  experiments  included
wo array  hybridizations  per  sample,  and  the  results  were
ecorded and  compared.  Only  genomic  imbalances  detected
n both  dye-swap  experiments  were  reported.
ata  Analysis
hole-genome  array-CGH  data  analyses  were  performed  in  a
linded fashion;  samples  were  received,  de-identiﬁed,  and
nvestigators who  performed  the  array-CGH  analyses  were
ot aware  of  the  previous  clinical  and  laboratory  information
elated to  each  sample.  The  DNA  copy  number  varia-
ions (CNVs)  detected  were  compared  with  CNVs  reported
n publicly  available  online  resources  and  databases  of
hromosomal abnormalities  and  variants.7--13 The  CNVs
gains/duplications or  losses/deletions)  were  classiﬁed  into
ifferent categories:  benign  CNV  (normal  genomic  variant);
NV of  uncertain  clinical  relevance  (variant  of  uncertain  sig-
iﬁcance [VOUS]);  and  CNV  of  possible  clinical  relevance
pathogenic variant).  In  this  study,  the  pathogenic  abnor-
alities included  the  detection  of  CNVs  in  known  pathogenic
egions, deletion/duplication  >  3  Mb  in  size,  or  visible  by  G-
anded  karyotype  that  have  not  been  reported  in  the  normal
opulation, and  deletions  or  duplications  <  3  Mb  previously
eported as  pathogenic.  Benign  deletions  or  duplications
ncluded variants  well  documented  in  the  normal  population
r previously  reported  as  benign.  Deletions  or  duplications
ere classiﬁed  as  being  VOUS  when  insufﬁcient  evidence
as available  to  conclude  if  the  CNV  was  either  pathogenic
r benign.
esults
he  data  of  the  35  neonates  with  congenital  anomalies  of
nknown cause,  born  between  July  of  2011  and  December  of
012, whose  DNA  samples  were  analyzed  by  whole-genome
rray-CGH, are  presented  in  Table  1.  The  maternal  age
anged from  16  to  41  years  of  age.  This  study  identiﬁed
2 (34.3%)  cases  with  DNA  copy  number  variations  (CNVs).
rom those  cases,  7/12  (58.3%)  were  male  and  5/12  (41.7%)
ere female.  The  details  of  the  array-CGH  results  from  the
ases with  genomic  imbalances  are  summarized  in  Table  2.
hirteen CNVs  were  identiﬁed  in  12  individuals.  Overall,
uplications were  veriﬁed  in  6/35  (17%)  and  deletions  were
eriﬁed in  7/35  (20%)  of  the  cases.  In  6/35  (17%)  of  the  cases,
nly a  deletion  was  identiﬁed;  5/35  cases  (14.3%)  only  had
 duplication,  and  1/35  (2.8%)  had  a  deletion  and  a  dupli-
ation. Additionally,  a  FISH  test  conﬁrmed  the  array-CGH
esults in  one  deletion  case  (case  14)  from  which  stored  cells
ere available  (data  not  shown).
Among  the  ﬁve  individuals  with  syndromic  or  non-yndromic orofacial  clefts  (cases  14,  25,  30,  34,  and  37)
n whom  genomic  imbalances  were  detected,  one  case
xhibited a  clinically  signiﬁcant  7.2  Mb  deletion  at  chro-
osome 17p13.3-p13.1  (case  14)  that  coincides  with  the
62  Emy  Dorfman  L  et  al.
A B
chr1 chr4 chr6 chr10 chr17
C D E
210–1–2210–1–2210–1–2210–1–2 210–1–2
Figure  1  Array-CGH  ratio  proﬁles  of  the  chromosomes  in  four  neonates  with  pathogenic  chromosomal  imbalances  using  genomic
DNA  from  the  neonates  as  test  (in  red)  and  DNA  from  normal  subjects  as  reference  (in  blue).  The  test/reference  ratio  data  for  each
chromosome  are  shown.  Each  dot  represents  a  single  probe  (oligo)  spotted  on  the  array.  The  log  ratio  of  the  chromosome  probes
is  plotted  as  a  function  of  chromosomal  position.  Copy  number  loss  shifts  the  ratio  to  the  left  (value  of  approximately  -1x).  Copy
number  gain  shifts  the  ratio  to  the  right  (value  of  approximately  +1x).  The  ideogram  of  each  chromosome  (left  margin)  shows  the
location  of  each  probe.  The  probe  log2  ratios  were  plotted  according  to  genomic  coordinates  (based  on  the  UCSC  Genome  Browser,
February  2009,  NCBI  Build  37  reference  sequence).  A:  A  ∼1.5  Mb  terminal  deletion  at  chromosome  1q44  (blue  line)  in  case  31.
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g:  A  ∼12.9  Mb  terminal  deletion  at  chromosome  4p16.3-p15.3
hromosome  6q22.31-q37  (blue  box)  in  case  31.  D:  A  ∼  2.37  Mb
 ∼  7.2  Mb  terminal  deletion  at  chromosome  17p13.3-p13.1  (bl
nown  Miller-Dieker  syndrome  (MDS)  region.  FISH  analysis
onﬁrmed the  deletion  of  the  chromosome  17p13.3  region
data not  shown).  The  other  four  cases  with  oral  facial  clefts
howed CNVs  that  were  classiﬁed  as  benign  or  as  VOUS.  Of
he two  cases  with  arthrogryposis  multiplex  congenital  (17
nd  31),  in  one  individual  an  interstitial  duplication  of  the
ong arm  of  chromosome  6  at  band  q22.31-q27  was  found,
s well  as  a  terminal  deletion  of  the  long  arm  of  chromo-
ome 1  at  band  q44.  The  previous  karyotype  analysis  showed
he identiﬁcation  of  a  chromosomal  abnormality  of  unknown
rigin involving  the  long  arm  of  chromosome  6,  but  not  the
hromosomal imbalance  that  involved  chromosome  1.  This
nfant died  at  the  age  of  35  days.  Of  ﬁve  additional  cases
ith MCAs  (1,  16,  22,  38,  and  48),  this  study  identiﬁed
linically signiﬁcant  chromosomal  imbalances  or  potential
D
T
ilue  box)  in  case  1.  C:  A  ∼  49.7  Mb  interstitial  duplication  at
inal  deletion  at  chromosome  10q26.3  (blue  box)  in  case  48.  E:
ox)  in  case  14.
athogenic  CNVs  in  three  cases  (1,  31,  and  48).  The  sub-
ects died  at  the  age  of  2  days,  5  hours,  and  3  days  after
irth, respectively.  Overall,  the  deletions  were  classiﬁed  as
athogenic in  three  cases  (1,  14,  and  48),  as  benign  in  two
ases (16  and  30),  and  as  VOUS  in  two  cases  (17  and  31).
he duplications  were  classiﬁed  as  pathogenic  in  one  case
31), as  benign  in  two  cases  (34  and  38),  and  as  VOUS  in
hree cases  (cases  22,  25,  and  37).  Examples  of  array-CGH
raphical overviews  are  shown  in  Fig.  1.iscussion
he  aim  of  this  study  was  to  retrospectively  identify  genomic
mbalances using  whole-genome  array-CGH  in  samples
Array  CGH  in  neonates  with  congenital  anomalies  
Table  1  Summary  of  the  clinical  indications  from  the  35
samples at  the  time  of  referral  for  chromosomal  analysis.
Case  Main  clinical  associated  features
1a Female,  CDH,  microtia,  hypertelorism,  CHD
(dextroposition  of  the  heart),  anal  atresia
2 Male,  CHD  (tetralogy  of  Fallot)
4  Male,  omphalocele,  microcephaly
5  Male,  omphalocele,  limb  agenesis,  ambiguous
genitalia,  anal  atresia,  bladder  dysfunction
10 Female,  gastroschisis
12a Male,  CDH
13 Male,  unilateral  phocomelia,  hip  dysplasia
14 Male,  cranial  asymmetry,  cleft  palate  (soft),  ocular
hypertelorism,  esophageal  atresia  type  IIIB,
camptodactyly  of  the  3rd,  4th,  and  5th  ﬁngers,
clinodactyly  of  the  5th  ﬁnger,  clubfeet
15  Male,  anal  atresia,  club  feet
16  Female,  anal  atresia,  hypoplastic  genitalia,  CHD
17 Female,  arthrogryposis  multiplex  congenital
(amyoplasia)
19 Female,  non-syndromic  unilateral  cleft  lip  (left)  and
cleft  palate
22a Female,  microcephaly,  cerebellar  hypoplasia,
olygohydramnios,  pulmonary  hypoplasia,  renal
dysplasia,  genital  hypoplasia,  frontal  microgyria,
occipital  encephalocoele,  cerebellar  hypoplasia
23 Female,  omphalocele,  microcephaly
24  Male,  micrognathia,  single  upper  median  incisor
25 Female,  non-syndromic  cleft  lip  and  palate
(bilateral)
29 Male,  CHD  (tetralogy  of  Fallot)
30  Male,  non-syndromic  cleft  lip  and  palate  (bilateral)
31a Male,  arthrogryposis  multiplex  congenita
(amyoplasia),  CHD  (tetralogy  of  Fallot),  hip  dysplasia
32a Female,  bilateral  multicystic  dysplastic  kidney,
oligohydramnios
33 Male,  cleft  palate,  clubfeet
34  Male,  cleft  lip  (left)  and  cleft  palate,  widow’s  peak,
widely  spaced  nipples,  genital  hypoplasia,
hypospadias
35 Female,  HPE,  oligohydramnios,  microcephaly,
unilateral  choanal  atresia
37  Male,  non-syndromic  cleft  lip  and  palate  (bilateral)
38 Male,  esophageal  atresia  type  IIIB
40 Male,  intrauterine  growth  retardation
41  Female,  gastrosquisis
42  Female,  CHD  (tetralogy  of  Fallot)
43  Male,  non-syndromic  cleft  palate
44  Male,  microgyria,  incomplete  lissencephaly,
micrognathia
46 Male,  meningocele,  club  foot  (left)
47  Female,  gastroschisis
48a Male,  bilateral  multicystic  dysplastic  kidney,
oligohydramnios,  bilateral  pulmonary  hypoplasia
49 Female,  gastroschisis
50  Male,  arthrogryposis  multiplex  congenita,
micrognathia
CDH, congenital diaphragmatic hernia; CHD, congenital heart
defect;  HPE, holoprosencephaly.
a Patient died.
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vailable  from  neonates  with  congenital  anomalies  of
nknown etiology.  In  addition,  this  study  evaluated  the
ontribution of  array-CGH  as  a  ﬁrst-line  diagnostic  tool
n neonates  with  congenital  anomalies  in  a  birth  defects
onitoring program  at  a  public  maternity  hospital  in
outhern Brazil.
To  date,  the  largest  newborn  screening  (in  20,126  unse-
ected cases)  using  array-CGH  analysis  as  a  ﬁrst-line  test
evealed that  87/20,126  (0.43%)  of  the  neonatal  cases  had
hromosomal imbalances  (53  cases  of  aneuploidies,  23  dele-
ions, and  11  duplications).4
Reddy  et  al.14 reported  the  results  of  a  population-based
tudy of  532  stillbirths.  In  this  sample,  array-CGH  analysis
ielded more  results  than  did  karyotype  analysis  (87.4%  vs.
0.5%), provided  better  detection  of  genetic  abnormalities
aneuploidy or  pathogenic  CNVs,  8.3%  vs.  5.8%),  and  also
dentiﬁed more  genomic  imbalances  among  67  stillbirths
ith congenital  anomalies  (29.9%  vs.  19.4%).
When  selective  screening  is  performed,  the  use  of
rray-based technologies  demonstrates  the  ability  to
etect pathogenic  imbalances  in  approximately  14%-18%  of
ostnatal cases  with  developmental  delays,  intellectual  dis-
bilities, and  MCAs  referred  for  analysis.2,15--18 The  present
tudy veriﬁed  genomic  imbalances  in  4/35  (14.3%)  of  the
ases that  could  be  deﬁned  as  pathogenic  and  causally
elated to  the  abnormal  phenotypes.  Although  this  study  was
erformed in  a  relatively  small  cohort,  the  rate  of  positive
ndings detected  through  array-CGH  is  in  the  range  reported
n several  postnatal  series.
Although  a  clear  association  exists  between  CNVs  in  both
yndromic and  non-syndromic  congenital  anomalies,  only
ew large  cohort  studies  have  speciﬁcally  performed  whole-
enome array-CGH  analysis  in  samples  of  neonates  with
irth defects.  Lu  et  al.19 reported  the  frequency  of  genomic
mbalances identiﬁed  in  638  neonates  with  various  birth
efects referred  for  chromosomal  microarray  analysis.  They
sed  three  different  array  platforms  with  increasingly  exten-
ive genomic  coverage  and  compared  the  results  obtained.
verall, 17.1%  of  patients  were  identiﬁed  with  clinically  sig-
iﬁcant abnormalities,  with  detection  rates  of  13.7%,  16.6%,
nd 19.9%,  depending  on  the  array  platform  used.
In  the  present  study,  a  previous  karyotype  analysis
as available  in  32  cases  and  showed  that  the  frequency
f chromosomal  imbalances  detected  was  1/32  (3.1%).
he detection  yield  of  genomic  imbalances  not  previously
etected by  karyotype  analysis  increased  to  9/32  cases  (28%)
ith the  use  of  array-CGH,  which  was  in  agreement  with  the
xpected increased  detection  yield.  In  4/35  cases  (11.4%),
NVs could  be  deﬁned  as  pathogenic  and  causally  related  to
he abnormal  phenotypes.  Rate  differences  between  differ-
nt studies  may  be  due  to  the  cohort  size,  differences  in  the
esolution of  the  array  platform  used,  the  criteria  for  patient
election, and  the  interpretation  of  the  clinical  relevance  of
he CNVs.
Among the  4/35  pathogenic  cases,  in  two  cases  (31
nd 48),  the  identiﬁed  abnormalities  found  had  not  been
reviously associated  with  well-recognized  syndromes.  In
he two  other  cases  (1  and  14),  causative  alterations
ad already  been  associated  with  well-deﬁned  microdele-
ion syndromes20 (Wolf-Hirschhorn  Syndrome  [WHS]  and
DS, respectively).  In  these  two  cases  with  CNVs  associ-
ted with  well-deﬁned  genetic  disorders,  the  chromosomal
64  Emy  Dorfman  L  et  al.
Table  2  Details  of  the  array-CGH  from  12  samples  with  chromosomal  imbalances.
Case  Del/Dup  Chromosome
band  location
Size  (Mb)  Genomic
coordinates
(hg  19)
Classiﬁcation Main  clinical  associated
features
1a del  4p16.3-p15.33  12.90  71,552-12,976,346  Pathogenic  Female,  CDH,  microtia,
hypertelorism,  CHD
(dextroposition  of  the  heart),
anal atresia
14 del  17p13.3-p13.1  7.22  87,309-7,306,339  Pathogenic  Male,  cranial  asymmetry,  cleft
palate  (soft),  ocular
hypertelorism,  esophageal
atresia type  IIIB,
camptodactyly,  clinodactyly  of
the  ﬁfth  ﬁnger,  clubfeet
16 del  8p11.2  0.13  39,258,894-39,386,158  Benign  Female,  anal  atresia,  club  feet
17  del  11p14.2-p14.1  0.22  27,006,061-27,225,374  VOUS  Female,  distal  arthrogryposis,
club feet
22a dup  9q31.3-q32  1.53  113,919,284-115,449,137  VOUS  Female,  microcephaly,
cerebellar  hypoplasia,
olygohydramnios,  pulmonary
hypoplasia, renal  dysplasia,
genital hypoplasia,  frontal
microgyria, occipital
encephalocele,  cerebellar
hypoplasia
25 dup  9p13.3-p13.2  1.89  36,163,040-38,050,778  VOUS  Female,  non-syndromic  cleft
lip  and  palate  (bilateral)
30 del  15q11.1-.q11.2  1.91  20,575,646-22,486,999  Benign  Male,  non-syndromic  cleft  lip
and  palate  (bilateral)
31a del  1q44  1.52  247,695,693-249,212,668  VOUS  Male,  arthrogryposis  multiplex
congenita (amyoplasia),  CHD
(Tetralogy of  Fallot),  hip
dysplasia
dup 6q22.31-q27  49.75  118,718,417-168,473,515  Pathogenic
34 dup  22q11.23  0.23  25,664,618-25,892,253  Benign  Male,  cleft  lip  (left)  and  cleft
palate, widow’s  peak,  widely
spaced nipples,  genital
hypoplasia, hypospadias
37 dup  3q29  0.19  197,574,293-197,766,791  VOUS  Male,  non-syndromic  cleft  lip
and  palate  (bilateral)
38 dup  2p22.3  0.64  32,654,837-33,294,782  Benign  Male,  esophageal  atresia  type
IIIB
48a del  10q26.3  2.37  132,720,766-135,089,504  Pathogenic  Male,  bilateral  multicystic
dysplastic kidney,
oligohydramnios,  bilateral
pulmonary hypoplasia
CDH, congenital diaphragmatic hernia; CHD, congenital heart defect; VOUS, variant of uncertain signiﬁcance; array-CGH, microarray-
based comparative genomic hybridization; del, deletion; dup, duplication.
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mbalances  could  have  been  previously  diagnosed  by  karyo-
ype analysis  or  by  FISH  analysis  alone  (using  locus-speciﬁc
robes for  the  critical  chromosome  region)  if  the  clinical
ndings at  the  time  of  referral  were  indicative  of  a  par-
icular microdeletion  syndrome  that  could  inform  exactly
hich region(s)  and/or  chromosome(s)  to  investigate.  How-
ver, both  samples  were  from  subjects  in  whom  neither
b
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daryotype  nor  FISH  analysis  results  were  available.  Certain
enetic disorders,  such  as  WHS  and  MDS,  are  microdeletion
yndromes with  CNV  of  variable  size  known  to  be  caused
y dosage-sensitive  genes,  and  atypical  recognized  syn-
romes associated  with  non-recurrent  microdeletions  might
e clinically  missed  at  birth.  Furthermore,  even  in  a  well-
eﬁned syndrome,  non-recurrent  chromosome  deletions  can
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be  of  different  sizes,  leading  to  a  broad  phenotypic  spec-
trum.
One of  the  two  cases  with  arthrogryposis  multiplex
congenita (case  31)  showed  a  large  duplication  of  the
long arm  of  chromosome  6  at  bands  q22.31-q27  and  a
smaller deletion  of  the  long  arm  of  chromosome  1  at  band
q44. The  retrieval  of  laboratory  records  showed  that  a
chromosomal abnormality  of  unknown  origin  involving  the
long arm  of  chromosome  6  was  previously  recorded,  but
no chromosomal  imbalance  involving  chromosome  1  was
identiﬁed. At  that  time,  there  was  an  expectation  that
parental karyotypes  would  be  performed  to  better  deﬁne
the type  and  origin  (de  novo  or  familial)  of  the  extra
material on  chromosome  6.  Array-CGH  analysis  allowed  for
additional genomic  information  regarding  the  previously
identiﬁed duplication  at  chromosome  6  and  the  detection
of an  additional  genomic  imbalance  (deletion  at  chromo-
some 1)  that  was  not  previously  reported.  Frequently,  more
than one  CNV  is  identiﬁed  in  an  individual.  It  is  evident
already from  the  karyotype  analysis  that  the  chromosome
duplications must  involve  many  genes  and  be  causally
related to  the  congenital  anomalies,  as  assumed  in  case
31. However,  it  has  been  recognized  that  the  presence
of another  CNV  could  reduce  or  aggravate  the  clinical
phenotype.21,22
From  the  two  samples  with  syndromic  cleft  lip  and/or
cleft palate  (cases  14  and  34)  and  the  three  with  non-
syndromic cleft  lip  and  cleft  palate  (cases  25,  30,  and
37), one  case  (14)  had  a  clinically  signiﬁcant  7.2  Mb  dele-
tion at  chromosome  17p13.3-p13.1  that  coincides  with  the
known MDS  microdeletion  syndrome.  In  the  other  four
cases, benign  CNVs  (30  and  34)  or  VOUS  were  identi-
ﬁed (cases  25  and  37).  Approximately  30%  of  cleft  lip
and palate  cases  and  50%  of  cleft  palate  cases  are  rec-
ognized as  components  of  MCA  syndromes.23 However,
both genetic  and  environmental  factors  are  known  to
contribute to  the  occurrence  of  cleft  lip  and  palate,  com-
plicating the  elucidation  of  the  causative  mechanisms.
Considerable efforts  have  been  made  in  seeking  candidate
gene(s) for  non-syndromic  clefts  through  array-CGH,  show-
ing that  it  is  an  effective  method  for  isolating  candidate
loci.24,25
The  clinical  relevance  of  5/13  (36.7%)  CNVs  among
the 12  cases  with  genomic  imbalances  remains  uncertain
at present,  as  there  is  insufﬁcient  evidence  to  conclude
whether the  CNVs  were  either  pathogenic  or  benign.  When
CNVs are  detected  that  have  no  strong  track  record  for
clinical importance,  the  interpretation  of  whether  they  are
causal for  the  birth  defect  can  be  challenging.  It  should  also
be considered  that  the  CNV  is  potentially  inherited  from
a healthy  parent  and,  in  this  case,  could  be  a  pathogenic
variant with  incomplete  penetrance  or  a  benign  familiar
variation. The  highly  variable  nature  of  the  genome  means
that care  must  be  taken  in  assigning  pathogenicity  to  CNVs
detected by  array-CGH.  From  the  CNVs  classiﬁed  as  VOUS  in
this study,  it  might  be  expected  that  parental  studies  would
be performed  to  allow  a  better  interpretation  and  to  provide
valuable information  for  genetic  counseling  prior  to  a  future
pregnancy. Indeed,  it  is  important  to  report  data  on  chromo-
some imbalances  with  unclear  clinical  signiﬁcance,  because
some of  the  data  may  represent  recurrent  CNVs  that  could  be
p
i
a65
ssociated  with  novel  syndromes.  Reports  of  patients  with
imilar genomic  imbalances  and  clinical  ﬁndings  can  lead  to
he identiﬁcation  of  newly  recognized  genomic  disorders  or
andidate genes  associated  with  isolated  congenital  anoma-
ies.
In four  cases  (16,  30,  34,  and  38),  normal  variants  clas-
iﬁed as  benign  were  detected.  It  is  recognized  that  all
umans differ  in  their  chromosomes  at  the  submicroscopic
evel and  that  even  the  genomes  of  normal,  healthy  indi-
iduals have  a  high  number  of  copy  number  changes.26
hen  several  individuals  were  screened  for  CNVs,  a  total  of
,447 copy  number  variable  regions  covering  360  Mb  (12%  of
enome) were  identiﬁed.27 CNVs  are  often  relatively  small,
an be  inherited  from  a  phenotypically  normal  parent,  occur
n more  gene-sparse  chromosomal  regions,  and  contain  more
epetitive DNA  sequences.  The  detection  of  benign  CNVs  was
eported in  this  study  from  genomic  regions  that  consistently
arbor benign  variants;  this  might  reduce  the  need  to  per-
orm parental  studies  in  neonates  in  whom  proven  benign
NVs were  identiﬁed.
A  limitation  of  this  study  was  the  inability  to  distin-
uish de  novo  from  inherited  genomic  imbalances  due
o the  unavailability  of  parental  DNA.  De  novo  CNVs  in
linically signiﬁcant  gene  regions  are  more  likely  to  be
ausative. However,  inherited  pathogenic  CNVs  should  not
e  excluded  as  a  cause  of  congenital  anomalies  because  of
heir variable  expressivity  and  incomplete  penetrance.28,29
athogenic  CNVs  may  be  inherited  from  an  apparently  nor-
al parent  and  contribute  to  the  abnormal  phenotype  in
he child.  These  types  of  CNVs  are  thought  of  as  suscep-
ibility loci,  in  that  they  increase  the  chance  of  a  child
eveloping congenital  anomalies  but  may  not  be  sufﬁcient
o cause  a  phenotype  by  themselves.  Parental  studies  should
e recommended  for  individuals  for  whom  clinically  sig-
iﬁcant ﬁndings  were  reported,  to  determine  whether  the
NV ﬁndings  represent  de  novo  or  familiar  events.  In  cases
f a  de  novo  chromosome  imbalance,  it  is  also  recom-
ended to  obtain  the  parental  karyotype  in  order  to  exclude
 balanced  translocation  in  one  of  the  parents.  Although
everal common  strategies  have  been  proposed  to  help
nterpret the  ﬁndings  of  genomic  imbalances,29,30 there  are
o universal  criteria  thus  far.  It  is  essential  to  have  the
ost accurate  and  up-to-date  information  on  the  clini-
al signiﬁcance  of  detected  genomic  imbalances,  as  well
s CNVs  at  different  positions  in  the  genome,  pathogenic
utations or  polymorphisms  in  other  individual  genes,  or
ongenetic causes  that  might  be  required  for  a  congen-
tal anomaly  to  be  expressed.  Caution  must  be  taken  in
he clinical  interpretation  of  the  array-CGH  results.  Fur-
her consultations  at  genetics  clinics  and  extended  analysis
n family  members  may  be  necessary  to  provide  accurate
ounseling to  the  families  and  to  calculate  the  recurrence
isks.
A typical  weakness  of  retrospective  studies  is  the  limited
linical information  available.  The  present  study  retrieved
he clinical  information  available  from  the  hospital  records
uring the  ﬁrst  referral.  Most  of  these  were  recorded  at  the
ime of  the  ﬁrst  laboratory  requirements  and  were  therefore
reliminary. Of  note,  6/35  (17%)  neonates  with  congen-
tal anomalies  died  soon  after  birth.  Nevertheless,  the
uthors consider  this  cohort  representative  of  the  neonates
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n  whom  the  presence  of  chromosomal  imbalances  was  sus-
ected.
This  study  demonstrated  the  feasibility  and  usefulness
f array-CGH  to  identify  deletions  and  duplications  in
tored DNA  samples.  It  was  shown  that  a  proportion  of
eonates with  congenital  anomalies  of  unknown  cause  had
hromosomal imbalances  associated  with  their  phenotypes.
urthermore, this  study  demonstrated  the  detection  of
hromosomal abnormalities  consistent  with  genetic  syn-
romes at  an  early  age,  when  often,  only  a  few  clinical
ndings are  clear.
In conclusion,  retrospective  or  prospective  array-CGH  as
 ﬁrst-line  diagnostic  tool  would  beneﬁt  families  by  pro-
iding a  more  accurate  diagnosis  and  impact  the  overall
anagement in  a  signiﬁcant  number  of  cases  from  birth
efects monitoring  programs.
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